Ruth Okediji discusses the Biden administration's recent proposal to use federal "march-in" rights to lower drug costs.
“This nod by the Biden administration to the serious challenge of access to medicines may contribute to the eventual resolution of a long-standing national problem.”
Read more in Harvard Law Today.
You might also like
- communityThe apocalypse that wasn’t